Zenith Health Care Ltd.
Snapshot View

View in App

Prices View details

6.28 -0.25 ▼-3.8%

20 May 2022, 04:01:00 PM
Volume: 86,229

Overview View Details

Sector Healthcare Compare with Sector peers
Industry Pharmaceuticals & Drugs Compare with Industry peers
Website http://www.zenithhealthcare.com
Market Cap 33.86 Cr.
Enterprise Value(EV) 31.32 Cr. 2021-09
Financial Indicators
Earnings per share (EPS) 0.07 Trailing Twelve Months Ending 2021-12
Price-Earning Ratio (PE) 88.40 Trailing Twelve Months Ending 2021-12
Industry PE 29.26 Trailing Twelve Months Ending 2021-12
Book Value / Share 1.37 Trailing Twelve Months Ending 2021-12
Price to Book Value 4.60 Calculated using Price: 6.30
Dividend Yield 0.00 Period Ending 2021-03
No. of Shares Subscribed 5.37 Cr. 53,739,000 Shares
FaceValue 1
Company Profile

Zenith Healthcare was incorporated in the year 1994. The company has its registered and corporate office located at Ahmedabad, Gujarat.

The company has its manufacturing facilities located at Changodar, Gujarat and has installed capacity to manufacture 168 million tablets, 37.5 million capsules and 90 million liquids.

Business area of the company:-

Zenith Healthcare is engaged in the manufacturing of tablets, capsules, ointments, and liquid injectable among others.

Delivery View Details

Delivered Qty
Traded Qty

Performance View Details

1 Day
-3.83%
1 Week
-1.88%
1 Month
-12.17%
3 Month
-18.44%
6 Month
-8.85%
1 Year
-24.15%
2 Year
+528.00%
5 Year
+503.85%
10 Year
+1131.37%

Ratios View Details

9 years 2013-03 2014-03 2015-03 2016-03 2017-03 2018-03 2019-03 2020-03 2021-03
Return on Equity (%) 0.14 -4.37 -4.06 -5.45 -2.78 4.95 2.38 9.27 6.64
Return on Capital Employed (%) 0.19 -6.48 -5.82 -8.24 -3.04 7.38 2.95 9.68 8.60
Return on Assets (%) 0.12 -3.90 -3.73 -5.00 -2.55 4.37 2.03 7.60 5.28

Balance Sheet View Details

Particulars 10 years 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2021-09* Rs. Cr.
Shh. Funds 6 6 6 6 5 6 6 6 7 7
Non Curr. Liab. 0 0 0 0 0 0 0 0 0 0
Curr. Liab. 1 1 1 1 1 1 1 2 2 3
Minority Int.
Equity & Liab. 7 7 6 6 6 7 7 8 8 10
Non Curr. Assets 3 3 3 2 2 2 2 2 2 2
Curr. Assets 5 4 4 4 4 5 5 6 6 8
Misc. Exp. not W/O
Total Assets 7 7 6 6 6 7 7 8 8 10

Profit Loss View Details

Particulars 10 years 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2021-12 Rs. Cr. TTM
Net Sales 4 3 4 3 5 10 10 12 14 16
Other Income 0 0 0 0 0 0 0 0 0 0
Total Income 4 3 4 4 5 10 10 12 14 17
Total Expenditure -4 -4 -4 -4 -5 -9 -10 -11 -13 -16
PBIDT 0 0 0 0 0 1 0 1 1 1
Interest 0 0 0 0 0 0 0
Depreciation 0 0 0 0 0 0 0 0 0 0
Taxation 0 0 0 0 0 0 0 0 0
Exceptional Items 0 0
PAT 0 0 0 0 0 0 0 1 0 0
Adjusted EPS 0 0 0 0 0 0 0 0 0

Cash Flow View Details

Particulars 10 years 2012-03 Rs. Cr. 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr.
Cash Fr. Operatn. 0 0 0 0 0 0 1 0 2 -1
Cash Fr. Inv. 0 0 0 0 0 0 0 0 -1 0
Cash Fr. Finan. 0 0 0 0 0
Net Change 0 0 -1 0 0 0 0 0 1 -2
Cash & Cash Eqvt 1 1 0 0 1 1 1 1 2 1

Shareholding Pattern View Details

9 Qtrs 2020-03 (%) 2020-06 (%) 2020-09 (%) 2020-12 (%) 2021-03 (%) 2021-06 (%) 2021-09 (%) 2021-12 (%) 2022-03 (%)
Promoter 28.74 28.74 28.74 28.74 28.74 28.74 28.74 28.74 28.74
Public 71.26 71.26 71.26 71.26 71.26 71.26 71.26 71.26 71.26
Depository Receipts 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Promoter Holding Pledge (%) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00

Announcements View Details

Fri, 20 May 2022
Board Meeting Intimation for Intimation Of Board Meeting To Be Held On Saturday May 28 2022
ZENITH HEALTH CARE LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 28/05/2022 inter alia to consider and approve Zenith Healthcare Ltd. informed BSE that the meeting of the Board of Directors of the Company is scheduled on 28/05/2022 inter alia to consider and approve the Audited Financial Results (Standalone) for the quarter and year ended on March 31 2022 and such other items as stated in notice.
Sat, 14 May 2022
Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A
Format of Initial Disclosure to be made by an entity identified as a Large Corporate.

Sr. No. Particulars Details
1Name of CompanyZENITH HEALTH CARE LTD.
2CIN NO.L24231GJ1994PLC023574
3 Outstanding borrowing of company as on 31st March / 31st December as applicable (in Rs cr) 0.00
4Highest Credit Rating during the previous FY NA
4aName of the Credit Rating Agency issuing the Credit Rating mentioned in (4)Not Applicable
5Name of Stock Exchange# in which the fine shall be paid in case of shortfall in the required borrowing under the frameworkBSE


We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26 2018. No



Name of the Company Secretary: MIHIR S SHAH
Designation: COMPANY SECRETARY
EmailId: mahendrazenith@hotmail.com
Name of the Chief Financial Officer: PRASHANT GUPTA
Designation: CHIEF FINANCIAL OFFICER
EmailId: mahendrazenith@hotmail.com

Date: 14/05/2022

Note: In terms para of 3.2(ii) of the circular beginning F.Y 2022 in the event of shortfall in the mandatory borrowing through debt securities a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore an entity identified as LC shall provide in its initial disclosure for a financial year the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets.
Sat, 16 Apr 2022
Format of the Annual Disclosure to be made by an entity identified as a Large Corporate
Format of the Annual Disclosure to be made by an entity identified as a Large Corporate.

Sr. No. Particulars Details
1 Name of Compay ZENITH HEALTH CARE LTD.
2 CIN L24231GJ1994PLC023574
3 Report filed for FY 2021-22
Details of the borrowings (all figures in Rs crore)
4 Incremental borrowing done in FY(a) 0
5 Mandatory borrowing to be done through issuance of debt securities(b) = (25% of a) 0
6 Actual borrowings done through debt securities in FY(c) 0
7 Shortfall in the mandatory borrowing through debt securities if any (d) = (b) - (c) { If the calculated value is zero or negative write nil} 0
8 Reasons for shortfall if any in mandatory borrowings through debt securities NOT APPLICABLE





Name of the Company Secretary :-MIHIR SHAH
Designation :-COMPANY SECRETARY and COMPLIANCE OFFICER
Name of the Chief Financial Officer :- Prashant Gupta
Designation : -Chief Financial Officer

Date: 16/04/2022

Technical Scans View Details

Fri, 20 May 2022
Higher Delivery Quantity Higher Delivery Quantity
Higher Trade Quantity Higher Trade Quantity
Higher Trade and Delivery Quantity Higher Trade and Delivery Quantity
Close Within 52 Week Low Zone Close Within 52 Week Low Zone
High Decrease 1 Month High Decrease 1 Month

Related Stocks View Details

Stock Name Market Cap(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. 219,659.12 915.50 +3.5%
Divi's Laboratories Ltd. 114,020.08 4,295.05 +2.2%
Cipla Ltd. 78,954.82 978.60 +4.3%
Dr. Reddy's Laboratories Ltd. 70,669.41 4,246.30 +8.1%
Apollo Hospitals Enterprise Ltd. 52,783.35 3,671.00 +1.0%
Gland Pharma Ltd. 50,388.39 3,061.70 -1.1%
Piramal Enterprises Ltd. 45,754.22 1,917.10 +1.2%
Stock Name Statement TTM Ending Price Earning Ratio(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-12 34.09 915.50 +3.5%
Divi's Laboratories Ltd. Consolidated 2021-12 44.40 4,295.05 +2.2%
Cipla Ltd. Consolidated 2022-03 31.37 978.60 +4.3%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 32.38 4,246.30 +8.1%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-12 46.57 3,671.00 +1.0%
Gland Pharma Ltd. Consolidated 2022-03 41.59 3,061.70 -1.1%
Piramal Enterprises Ltd. Consolidated 2021-12 36.83 1,917.10 +1.2%
Stock Name Statement TTM Ending Price To Book Value(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-12 4.25 915.50 +3.5%
Divi's Laboratories Ltd. Consolidated 2021-12 10.53 4,295.05 +2.2%
Cipla Ltd. Consolidated 2022-03 3.79 978.60 +4.3%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 3.68 4,246.30 +8.1%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-12 9.54 3,671.00 +1.0%
Gland Pharma Ltd. Consolidated 2022-03 7.04 3,061.70 -1.1%
Piramal Enterprises Ltd. Consolidated 2021-12 1.29 1,917.10 +1.2%
Stock Name Statement Year Ending Debt Equity Ratio LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 0.08 915.50 +3.5%
Divi's Laboratories Ltd. Consolidated 2021-03 0.00 4,295.05 +2.2%
Cipla Ltd. Consolidated 2021-03 0.10 978.60 +4.3%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 0.17 4,246.30 +8.1%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 0.62 3,671.00 +1.0%
Gland Pharma Ltd. Consolidated 2021-03 0.00 3,061.70 -1.1%
Piramal Enterprises Ltd. Consolidated 2021-03 1.16 1,917.10 +1.2%
Stock Name Statement Year Ending Return On Equity(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 4.98 915.50 +3.5%
Divi's Laboratories Ltd. Consolidated 2021-03 23.90 4,295.05 +2.2%
Cipla Ltd. Consolidated 2021-03 14.13 978.60 +4.3%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 11.53 4,246.30 +8.1%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 3.44 3,671.00 +1.0%
Gland Pharma Ltd. Consolidated 2021-03 20.97 3,061.70 -1.1%
Piramal Enterprises Ltd. Consolidated 2021-03 3.33 1,917.10 +1.2%
Stock Name Statement Year Ending Return On Capital Employed(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 4.98 915.50 +3.5%
Divi's Laboratories Ltd. Consolidated 2021-03 23.90 4,295.05 +2.2%
Cipla Ltd. Consolidated 2021-03 14.13 978.60 +4.3%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 11.53 4,246.30 +8.1%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 3.44 3,671.00 +1.0%
Gland Pharma Ltd. Consolidated 2021-03 20.97 3,061.70 -1.1%
Piramal Enterprises Ltd. Consolidated 2021-03 3.33 1,917.10 +1.2%
Stock Name Statement Year Ending Net Sales(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 33,498.14 915.50 +3.5%
Divi's Laboratories Ltd. Consolidated 2021-03 6,969.40 4,295.05 +2.2%
Cipla Ltd. Consolidated 2021-03 19,159.59 978.60 +4.3%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 19,047.50 4,246.30 +8.1%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 10,560.00 3,671.00 +1.0%
Gland Pharma Ltd. Consolidated 2021-03 3,462.88 3,061.70 -1.1%
Piramal Enterprises Ltd. Consolidated 2021-03 12,809.35 1,917.10 +1.2%
Stock Name Statement Year Ending Profit After Tax(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 2,284.68 915.50 +3.5%
Divi's Laboratories Ltd. Consolidated 2021-03 1,984.29 4,295.05 +2.2%
Cipla Ltd. Consolidated 2021-03 2,401.30 978.60 +4.3%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 1,903.60 4,246.30 +8.1%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 136.00 3,671.00 +1.0%
Gland Pharma Ltd. Consolidated 2021-03 996.96 3,061.70 -1.1%
Piramal Enterprises Ltd. Consolidated 2021-03 1,074.43 1,917.10 +1.2%